Ho Yeong Lim

机构：Samsung Medical Center, CHA University Bundang Medical Center, CHA University, Sungkyunkwan University · ORCID：0000-0001-9325-2300

发表论文 589 篇 · 总被引 40390 次 · h-index 79

代表论文

• Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial (2025 · Hepatology · 被引 16)
• Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study (2025 · JHEP Reports · 被引 12)
• Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC : An International Multicentre Study (2025 · Liver International · 被引 6)
• Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features (2025 · Clinical and Molecular Hepatology · 被引 5)
• Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age 20-39 Years (2026 · Journal of Clinical Oncology · 被引 4)
• Surgery or chemotherapy first? Unveiling the best approach for colorectal cancer with resectable liver metastasis (2025 · Surgery · 被引 3)